News & Updates

Show Multimedia Only
Carbapenem-sparing cephamycins effective in E coli-induced UTI

Carbapenem-sparing cephamycins effective in E coli-induced UTI

28 Oct 2022 byJairia Dela Cruz

Cefmetazole and cefoxitin prove to be effective in the treatment of patients with urinary tract infections (UTIs) due to extended-spectrum beta-lactamase (ESBL)–producing Escherichia coli, according to two separate studies presented at IDWeek 2022.

28 Oct 2022
Cemiplimab shows favourable signals as first-, second-line treatment alternative for NSCLC

Cemiplimab shows favourable signals as first-, second-line treatment alternative for NSCLC

28 Oct 2022 byAudrey Abella

In the 3-year follow-up of the EMPOWER-Lung 1 study, first-line cemiplimab continued to outdo chemotherapy (CT) in providing survival benefit for patients with advanced non-small-cell lung cancer (NSCLC). Moreover, in the second-line setting (patients with progressive disease [PD]), cemiplimab added to CT provided meaningful and durable objective response rate (ORR) and overall survival (OS) benefit.

28 Oct 2022
COVID-19 worsens antibiotic resistance

COVID-19 worsens antibiotic resistance

28 Oct 2022 byTristan Manalac

While rare, infection with antibiotic-resistant gram-negative bacteria (AR-GNB) following a positive COVID-19 diagnosis is more severe and often results in worse outcomes, according to a study presented at the recent Virtual ID Week 2022.

28 Oct 2022
Does cerebral embolic protection reduce stroke risk post-TAVR?

Does cerebral embolic protection reduce stroke risk post-TAVR?

27 Oct 2022 byRoshini Claire Anthony

The use of a cerebral embolic protection (CEP) device did not reduce the risk of periprocedural stroke in patients undergoing transcatheter aortic valve replacement (TAVR), according to results of the PROTECTED TAVR study presented at TCT 2022.

27 Oct 2022